Loprinzi C L, Schaid D J, Dose A M, Burnham N L, Jensen M D
Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905.
J Clin Oncol. 1993 Jan;11(1):152-4. doi: 10.1200/JCO.1993.11.1.152.
Randomized placebo-controlled clinical trials have now established that megestrol acetate causes appetite stimulation and weight gain in patients with anorexia and/or cachexia. There is a paucity of available data to delineate the substance of this increased weight.
Using dual-energy x-ray absorptiometry and tritiated body water methodologies, we performed body-composition measurements in 12 patients with advanced cancer before the institution of oral megestrol acetate (800 mg/d) and at subsequent 2-month intervals.
Seven of the 12 patients gained weight (2.1 to 16.5 kg) and had repeat body-composition measurements performed at the time of maximum weight gain. The vast majority of the gained weight was clearly from an increase in adipose tissue, while there was a suggestion that an increase in body fluid was responsible for a minority of the weight gain.
Megestrol acetate-induced weight gain is primarily the result of an increase in body mass.
随机安慰剂对照临床试验现已证实,醋酸甲地孕酮可刺激厌食和/或恶病质患者的食欲并导致体重增加。目前缺乏足够的数据来明确这种体重增加的实质。
我们使用双能X线吸收法和氚标记体水法,对12例晚期癌症患者在开始口服醋酸甲地孕酮(800毫克/天)之前以及随后每2个月进行一次身体成分测量。
12例患者中有7例体重增加(2.1至16.5千克),并在体重增加最多时再次进行了身体成分测量。增加的体重绝大多数明显来自脂肪组织的增加,同时有迹象表明,少数体重增加是由体液增加所致。
醋酸甲地孕酮引起的体重增加主要是体重增加的结果。